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Summary: The immune response upon infection with the pathogen
Mycobacterium tuberculosis is poorly understood, hampering the discovery
of new treatments and the improvements in diagnosis. In the last years,
a blood transcriptional signature in tuberculosis has provided knowl-
edge on the immune response occurring during active tuberculosis dis-
ease. This signature was absent in the majority of asymptomatic
individuals who are latently infected with M. tuberculosis (referred to as
latent). Using modular and pathway analyses of the complex data has
shown, now in multiple studies, that the signature of active tuberculo-
sis is dominated by overexpression of interferon-inducible genes
(consisting of both type I and type II interferon signaling), myeloid
genes, and inflammatory genes. There is also downregulation of genes
encoding B and T-cell function. The blood signature of tuberculosis
correlates with the extent of radiographic disease and is diminished
upon effective treatment suggesting the possibility of new improved
strategies to support diagnostic assays and methods for drug treatment
monitoring. The signature suggested a previously under-appreciated
role for type I interferons in development of active tuberculosis dis-
ease, and numerous mechanisms have now been uncovered to explain
how type I interferon impedes the protective response to M. tuberculosis
infection.
Keywords: tuberculosis, transcriptional signature, immune response
Introduction
The immune response underlying protection or pathogene-
sis in tuberculosis is incompletely understood, hindering
the development of new vaccines and therapeutics
(reviewed in 1). A third of the world is estimated to be
infected with Mycobacterium tuberculosis; however, only 10–
20% of individuals go on to develop active disease during
their lifetime, the rest remaining asymptomatic are referred
to as ‘latent’ (reviewed in 2). Furthering our understand-
ing of the immune response would be helpful in deter-
mining why some people exposed to M. tuberculosis remain
latent and others go to develop disease. Such knowledge
will also be useful for the development of vaccines and
therapeutics and may provide information required to sup-
port the identification of diagnostic and prognostic mark-
ers. Although M. tuberculosis antigen-specific interferon-
gamma (IFN-c) release assays can determine whether indi-
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viduals have been infected with M. tuberculosis, they cannot
distinguish individuals with active tuberculosis and those
latently infected with M. tuberculosis. This determination
relies on assessment of clinical symptoms and mycobacte-
rium sputum smear positivity, neither of which are highly
specific. Confirmatory diagnosis of tuberculosis requires
culture of the mycobacteria for speciation, which alterna-
tively can now be achieved using the nucleic acid amplifi-
cation testing (NAAT). Both are reliant on obtaining
sputum from infected individuals, which is not always fea-
sible, or bronchoalveolar lavage, which requires an inva-
sive technique not easily accessible in countries with a
high tuberculosis burden. Therefore, the ability to deter-
mine the immune response in active tuberculosis using
blood transcriptomics (3–10) offers new opportunities to
develop supportive biomarkers to determine whether indi-
viduals suffer from active tuberculosis. The diminished
blood transcriptomic signature observed during successful
tuberculosis treatment (4, 11, 12) could also help in mon-
itoring the response to treatment and in the development
of new drugs, since current tests for monitoring drug effi-
cacy such as the early bactericidal assays and 2-month spu-
tum conversion remain inadequate (13, 14). The immune
response uncovered using blood transcriptomics of active
tuberculosis has revealed hitherto unappreciated knowl-
edge, which may also be of great use in the development
of therapeutics.
A view of the immune response from the blood using
transcriptomics
Peripheral blood is easily accessible and represents a reser-
voir of immune cells trafficking to and from the sites of
active disease and lymphoid organs. The use of peripheral
blood for determining gene expression profiles in disease
was first introduced in studies of cancer (15–18) and then
autoimmune pathologies (19). More recently the blood
transcriptome has been of success in measuring the immune
response to infection (reviewed in 5) and can reflect disease
activity in the tissue (4). It has been shown that in some
cases blood transcriptional signatures may help to distin-
guish different infectious diseases, such as bacteria or
viruses, but can also distinguish between different bacterial
or viral infections (5, 20). In some cases, however, similar
transcriptional signatures can be observed in certain types of
diseases with similar pathogenesis (21–23) or infectious
agents (24). The specificity of the transcriptional signature
for a particular infectious disease requires a combination of
activated pathways and transcription programs, rather than a
set of uniquely activated disease-specific genes. Pathway and
modular bioinformatics analyses have been designed to
characterize a transcriptional response to identify combina-
tions of pathways and networks associated with diseases
(19, 25). Such approaches have been applied successfully to
the study of the immune response in tuberculosis (4, 12,
21). Methods for quantitation of transcriptomic profiles to
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reflect disease severity, such as the molecular distance to
health (MDTH) (25) or variations on this approach, have
been successfully developed and can also be used to quantify
the disease response to treatment (4, 11, 26).
Overview of transcriptomic studies in human
tuberculosis
Discrimination of active tuberculosis from latent
infection
Strategies to improve and/or support current diagnostic tests
for active tuberculosis would be of great use in clinical
management of the disease. The ability to provide an earlier
diagnosis of the disease would allow more rapid treatment
initiation, which could reduce the risk of transmission. Sup-
port and improvement of current diagnostic tests would also
minimize misdiagnosis of other confounding diseases as
tuberculosis and would thus avoid the adverse events result-
ing from unnecessary anti-tuberculosis treatment. This will
be particularly useful for diagnosis of tuberculosis in hard to
diagnose groups like infants and human immunodeficiency
virus (HIV)-infected individuals.
Several studies have reported the blood transcriptome of
patients with active tuberculosis (3, 5, 6) (Table 1). Early
studies in patients with active tuberculosis indicated that dif-
ferences existed between their blood gene expression pro-
files and those in healthy, latently infected individuals (27,
28). These early studies identified immune response genes
and chemokine genes to be differentially expressed in active
pulmonary tuberculosis patients and controls, but involved
small numbers of patients and required further validation. In
2010, a larger scale study was conducted, including patients
recruited in both London, U.K. and Cape Town, South
Africa, all recruited before initiation of treatment (4).
Whole genome blood transcriptomic profiles clearly dis-
criminated individuals with active tuberculosis from those
latently infected with M. tuberculosis and healthy controls (4).
Furthermore, the magnitude of the transcriptional signature
correlated with the extent of disease in the lungs as mea-
sured by radiography (4) (Fig. 1), indicating that the
immune response in the blood can reflect the local reaction
to a pathogen in the lung. The observed transcriptional sig-
nature was replicated in independent and validation cohorts
(4). The blood transcriptional signature, as defined by vari-
ous approaches including pathway and modular analysis,
was shown to consist of upregulated IFN-inducible genes
(both type I and type II), myeloid and inflammatory genes,
and downregulated transcripts encoding B and T-cell genes
(4). Flow cytometric analysis together with purification of
leukocyte populations from the blood of identical individu-
als revealed that the downregulation of T-cell genes was lar-
gely due to diminished numbers of subsets of CD4+ T-cell
effector and memory cells (4), possibly reflecting apoptosis
and/or migration to the infected lung. A parallel study also
demonstrated a blood transcriptional signature that could
distinguish patients with active tuberculosis from latently
infected individuals (8). Here, Fcc receptor 1B (FCGRIB)
was defined as the most differentially expressed gene and in
combination with four other markers gave high specificity
for discrimination of active tuberculosis from individuals
with latent infection and healthy controls. Elevated expres-
sion of innate immune-related genes, including Janus kinase
(JAK)-STAT pathway, sensing of microbial patterns by Toll-
Table 1. Different studies demonstrating use of transcriptional blood signatures to identify patients with active tuberculosis
Geographical region Year Sample Study design Key pathways Reference
South Africa 2007 Whole blood TB versus LTB – (28)
Germany 2007 PBMC TB versus LTB Fcc-receptor signalling (27)
UK and South Africa 2010 Whole blood TB versus LTB versus HC,
TB versus OD, TB treatment
IFN signaling (4)
The Gambia 2011 Whole blood TB versus LTB JAK–STAT pathway; IFN signaling; TLR (7)
USA & Brazil 2011 Whole blood TB versus LTB versus HC Interferon signaling (29)
South Africa 2011 Whole blood TB versus LTB versus HC – (8)
Germany 2012 Whole blood TB versus OD IFN signaling; Complement;
TLR signaling; Fcc-receptor signalling
(44)
South Africa 2012 Whole blood TB treatment – (11)
Indonesia 2012 PBMC TB versus HC, TB treatment IFN signaling (10)
South Africa, Malawi 2013 Whole blood TB versus OD, TB versus LTB – (30)
UK 2013 Whole Blood TB versus OD, TB treatment IFN signaling, Role of pattern recognition
receptors, Antigen presentation
(21)
South Africa 2013 Whole blood TB treatment Complement; B-cell markers; CD64 (12)
South Africa, Kenya, Malawi 2014 TB versus OD,
TB versus LTB
– (36)
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like receptors, and IFN signaling was also observed in active
tuberculosis and suggested a high degree of accuracy in dis-
criminating tuberculosis patients and latently infected donors
and that expression of these genes correlated with suscepti-
bility and resistance to tuberculosis (8).
Similarity between these two independent studies (4, 8)
was subsequently reported (7). Such whole blood gene
expression in tuberculosis patients, as well as in healthy
infected and uninfected individuals was also analyzed in an
additional cohort in The Gambia, West Africa and validated
against the previously identified signatures (4, 8, 27)
(Fig. 2). A unique combination of classical gene expression
analysis with pathway and functional association analysis
integrated with intra-individual expression correlations was
used and revealed high similarities of expression profiles
among different cohorts (7) (Fig. 2). This study identified a
network of Fcc receptor 1 signaling correlating with
transcriptional activity as the hallmark of gene expression in
tuberculosis (7) and validated the previously reported (4, 8)
functional gene clusters of immunoregulatory interactions
involving the JAK-STAT pathway, sensing of microbial
patterns by Toll-like receptors and IFN signaling. Collec-
tively, these reports first suggested that the use of blood
transcriptomics could provide a robust system for identifica-
tion and validation of biosignatures for tuberculosis, which
could support its diagnosis. In addition, the use of integrated
and novel bioinformatic analysis tools (4, 8) to interrogate
the blood transcriptional signature revealed novel insights
into functional immune and inflammatory networks underly-
ing the pathogenesis of tuberculosis.
A
B
Fig. 1. The blood transcriptional signature of active tuberculosis correlates with radiographic extent of disease in the lung. Hierarchical
clustering analysis and statistical filtering generated a gene tree (green, left of figure) of 393 transcripts, and an expression profile (vertical
columns) (4) (A) here shown for selected participants correlating with lung radiographic extent of disease. Each row of the heatmap represents
an individual transcript and each column an individual participant. Relative abundance of transcripts is shown as: over-abundant red; under-
abundant blue; median colored yellow. (B) The Weighted Molecular Distance to Health calculated for the transcriptional signature is shown
against the score for the radiographic extent of disease. Adapted from Berry et al., 2010, Nature (4).
© 2015 The Medical Research Council. Immunological Reviews published by John Wiley & Sons Ltd.
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Further studies describing discriminatory gene expression
profiles, which segregate individuals with active tuberculosis
from those asymptomatic individuals latently infected with
M. tuberculosis or from uninfected healthy control subjects,
have subsequently been published by several different
research groups. These studies have been conducted using a
variety of microarray platforms, and importantly patients
have been recruited in different geographical locations,
including Brazil (29), The Gambia (7), Indonesia (10),
South Africa, and Malawi (30), again supporting the robust-
ness of using whole blood gene expression profiles in the
identification of individuals with active tuberculosis as dis-
tinct from those latently infected individuals and healthy
controls. Although initially there were concerns that dis-
crimination might be masked unless cell subsets were char-
acterized separately, the IFN-inducible signature identified
by Berry et al. (4) was clearly observable directly in whole
blood from active tuberculosis patients versus controls.
The total transcript composition of whole blood can indi-
cate important differences in cell populations. Berry et al. (4)
reported that the whole blood IFN-inducible signature of
active tuberculosis was observed in purified neutrophils
from the same individuals, with a subset of the genes also
upregulated in purified monocytes. The blood transcriptome
of active tuberculosis showed a decrease in B-cell and T-cell-
specific genes (4), and flow cytometric analysis of the blood
from these patients revealed that the T-cell signature could
be explained by decreases in central and effector memory T
cells in the blood of active tuberculosis patients (4). This is
in keeping with accumulating evidence that the monocyte/
lymphocyte ratio is associated with the risk of developing
active tuberculosis following infection (31) and has been
observed in whole blood transcriptomic studies (Fletcher,
personal communication). Nevertheless, gene expression
profiling of selected CD4+ and CD8+ T cells provided a
highly discriminatory gene expression profile for active
tuberculosis versus latent infection (32). The identified
cytokine receptor signaling regulation included Interleukin
(IL-2) receptor a-chain, JAK3, suppressor of cytokine signal-
ing 3 (SOCS3), cytokine-inducible SH2-containing protein,
and protoncogene serine/threoinine protein kinase. It needs
to be clarified whether this regulatory signaling network
indeed contributes to impaired T-cell responses in tubercu-
losis.
A comparison (6) of eight independently obtained tuber-
culosis microarray datasets (4, 7, 8, 10, 12, 23, 27, 28)
revealed enrichment for genes associated with myeloid cell
inflammation and TREM1 signaling as the most significant
pathways upon integration of data from all the studies (6)
rather than the IFN signaling pathway (4, 8, 10). This
signature of myeloid inflammation had also been observed
in earlier studies using the modular approach (4, 12). Flow
cytometric analysis of leukocyte subsets isolated from the
blood of the same active tuberculosis patients indicated that
the pronounced myeloid signature resulted from increased
numbers of inflammatory monocytes and increased gene
expression in purified monocytes (4). True dominance of a
particular pathway will require quantitative analysis by other
more sophisticated approaches in the future. It is possible,
however, that in future in depth meta-analysis of the active
tuberculosis blood signature, when quantitatively compared
and including a larger set of confounding diseases in
increased numbers of individuals, may reveal yet another
dominant pathway or set of genes better able to distinguish
tuberculosis from other diseases and of use in diagnosis.
Regardless, it is likely that the different pathways of genes
perturbed during active tuberculosis may all contribute to
pathogenesis of the disease, such as the IFN-inducible genes
described in the blood signature of active tuberculosis (4, 7,
8, 10, 12).
Discrimination of active tuberculosis from other
confounding diseases
Remarkable similarities have been reported in the blood
transcriptome of individuals with tuberculosis and the gran-
ulomatous disease sarcoidosis (21–23). Sarcoidosis is a
multi-system granulomatous disease, predominantly a respi-
ratory disorder of unknown etiology, which presents with
very similar radiological and clinical findings to tuberculosis.
Both diseases were found to have significant overlap in the
Fig. 2. Comparison of differential expression in three independent
cohorts. Comparison of differential gene expression between active
tuberculosis (TB) and individuals with latently infected with
M. tuberculosis (LTBI) in cohorts in South Africa (SUN) and The Gambia
(MRC) with gene profiles in a cohort in the United Kingdom (UK)
and South Africa identified by Berry et al. (4). Significance of
differential expression at corrected p-value level of q < 0.05. From
Maertzdorf et al., 2011, Plos One (7).
© 2015 The Medical Research Council. Immunological Reviews published by John Wiley & Sons Ltd.
92 Immunological Reviews 264/2015
Cliff et al  Response to TB and treatment
differentially expressed genes in the blood, including the
IFN-inducible genes (21–23), indicating that common
pathways may result in the similar pathological features
observed in both diseases. In keeping with this theory,
another bacterial granulomatous disease affecting the lung,
melioidosis, also revealed some overlap with the IFN-domi-
nated blood transcriptional signature of pulmonary tubercu-
losis (33). On the other hand, patients with community-
acquired pneumonia and lung cancer were shown to display
a distinct blood transcriptional signature to that seen in tuber-
culosis, which instead is dominated by an inflammatory
signature (21) and not the dominant IFN-inducible signature
of tuberculosis and sarcoidosis. Transcript classifiers that
discriminated between tuberculosis were identified (21–23).
Around a quarter of all tuberculosis deaths occur in HIV-
infected people who often test negative for mycobacteria,
e.g. sputum smear negative (34), hence the ability to diag-
nose active tuberculosis in this group is vital for improved
patient care and tuberculosis control programs. The recent
identification of gene expression signatures that can distin-
guish individuals with active tuberculosis from those with
other lung diseases and in M. tuberculosis infection in HIV+
individuals is very encouraging (30). A large case–controlled
study, involving both HIV-infected and HIV-uninfected indi-
viduals, prospectively recruited patients presenting with
symptoms of tuberculosis, some of whom on further inves-
tigation were diagnosed with another disease and not tuber-
culosis. This study generated a large clinically relevant and
diverse cohort of confounding diseases to act as a compari-
son group with the positively identified tuberculosis cohorts
(30). The derived transcriptional signatures were able to dif-
ferentiate, with a high degree of sensitivity and specificity,
between tuberculosis and healthy controls as well as
between tuberculosis and other confounding diseases in
both HIV-infected and HIV-uninfected individuals (30).
Pediatric tuberculosis is notoriously difficult to diagnose and
often depends exclusively on clinical symptoms (35). The
characterization of an altered blood gene expression profile
in children with active tuberculosis comprising both HIV-
infected and HIV-uninfected individuals (36) provides new
leads for the development of new, host-based tests, to sup-
port the diagnosis of tuberculosis in pediatric disease (36)
in addition to adult disease (4, 7, 8, 10, 12, 21, 30).
What is needed for blood transcriptomics to support
diagnostics or prognostics?
To develop this approach and to verify proposed classifiers
as a support to current diagnostics, testing in further inde-
pendent cohorts will be necessary to evaluate diagnostic
accuracy, and additionally it will be necessary to validate
transcript classifiers in a range of independent cohorts of
respiratory and systemic illnesses. A dominant algorithm of
transcript classifiers, consisting of several sets of ca. 12–100
genes associated with active tuberculosis, may be the best
approach for the development of a diagnostic with the high-
est specificity and sensitivity, and this approach would be
required considering current costs in order to be of use in
the clinic. Yet, as technology advances for processing and
gene expression analysis together with advances in analytical
tools (37) and also becomes more affordable, it is possible
that a diagnosis may be based on the whole set of genes dis-
criminating tuberculosis from other diseases and on selected
classifier genes. The use of blood transcriptomics to improve
diagnosis of tuberculosis could be applied together with
current methods including clinical symptoms, sputum
mycobacterium smear positivity, and confirmatory diagno-
sis, where possible, of tuberculosis by culture or NAAT
technology. This will be especially valuable in cases who are
smear negative or culture negative, and in children where
such tests are not always feasible. Blood transcriptomics may
help to speed up diagnosis and predict which people have
disease, allowing faster treatment and thus reduction of
transmission.
Berry et al. (4) reported that the signature of active tuber-
culosis was detectable in 10–20% of asymptomatic individu-
als diagnosed with latent M. tuberculosis infection [by the
IGRA test, an M. tuberculosis specific antigen-stimulated IFN-c
release assay of human blood or the tuberculin skin test
(TST)-skin test], although this could be reflective of subclin-
ical tuberculosis at early stages of disease. This needs to be
verified in larger number of latently infected individuals,
and it will be of interest to determine whether those with a
signature of tuberculosis go on to develop disease or
whether their signature reverts to that of healthy controls
and the majority of latently infected individuals. This would
be in keeping with the heterogeneity in individuals who are
latently infected with M. tuberculosis that has been reported
using high-resolution computed tomography (CT) and posi-
tron emission tomography (PeT) (PET-CT) (2). Currently,
data from a longitudinal study which followed household
contacts of newly diagnosed tuberculosis patients over sev-
eral years is being analyzed. In this study, blood transcrip-
tome profiles are compared in those household contacts
who remained healthy over the observational period versus
those who developed active TB. It is hoped that this study
will provide a first hint about a biosignature that can
© 2015 The Medical Research Council. Immunological Reviews published by John Wiley & Sons Ltd.
Immunological Reviews 264/2015 93
Cliff et al  Response to TB and treatment
predict individuals at heightened risk of developing active
tuberculosis disease (9, 13, 38) (http://www.biomarkers-
for-tb.net/). Another ongoing study determines risk of
tuberculosis disease in adolescents living in a TB-high-
endemic area (39, 40).
Changes in blood gene expression during tuberculosis
treatment
Monitoring tuberculosis drug efficacy is important for both
clinical management and the development of new treatments.
Berry et al. (4) observed that the blood transcriptional signa-
ture of active tuberculosis, consisting largely of increased
IFN-induced gene expression, diminished by 2 months of
treatment and had disappeared by 12 months after diagnosis
(Fig. 3A). This change in the molecular signature paralleled
the clinical improvement measured by chest X-ray (Fig. 3B)
and was reflected in the MDTH score measured for individual
patients (Fig. 3C). The diminished T and B-cell signature of
active tuberculosis also reverted in some individuals after
2 months of treatment, but this change was most apparent in
all individuals by 12 months post-treatment (Fig. 3A). In two
separate subsequent longitudinal studies based in South Africa
(11, 12) and London (11), it was apparent that large-scale
changes in blood host gene expression occur very rapidly
after initiation of successful tuberculosis treatment (Fig. 3D
and E), with differences detectable after only 1 week of treat-
ment (Fig. 4). Slower changes continued to occur throughout
the duration of tuberculosis treatment (11, 12). Strikingly,
similar results were obtained from both longitudinal studies,
despite being conducted by different investigators using dif-
ferent technological platforms (Figs 3D, E and 4). Pathway
analysis showed certain genes changed expression immedi-
ately upon treatment initiation whereas others changed at
later times, indicating that different biological pathways may
predominantly be affected during different stages of treat-
ment and recovery. A rapid downregulation of genes
involved in the inflammatory response including a dominant
C1q complement element occurred first at 1 week postinfec-
tion (Fig. 4A and C) and was followed by changes in lympho-
cyte compartments with distinct upregulation of B-cell-
related genes (12) (Fig. 4B and C). Ottenhoff et al. (10) also
observed temporal changes in blood gene expression through
A D
E
B
C
0  1 2   4 26
Weeks
0 2 8 24 52
Weeks
Fig. 3. The blood transcriptional signature of tuberculosis is diminished upon successful treatment. (A) The transcriptional signature of
active TB is extinguished during treatment (4). (B) Transcriptional profiles of Active TB patients, resampled at 2 and 12 months
postantimycobacterial drug treatment were compared with baseline and compared to X-ray (4). (C) The Weighted Molecular Distance to Health
calculated for the transcriptional signature is shown against the time after treatment (A–C From Berry et al., Nature 2010) (4). (D) A blood
transcript signature is seen to change on treatment by as early as 1 week (12) ‘Cliff et al., Distinct phases of blood gene expression pattern
through tuberculosis treatment reflect modulation of the humoral immune response. (From Cliff et al., J Infect Dis 2013; 207(1): pp. 18–29, by
permission of Oxford University Press’ (E) A 664 transcript signature is seen to change on treatment by as early as 2 weeks (From Bloom et al.,
Plos One 2012) (11).
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treatment, in samples collected from Indonesian tuberculosis
patients (10), with expression patterns after 8 weeks being
intermediate to the profiles obtained at tuberculosis diagnosis
and at the end of treatment. Samples from healthy control
subjects were similar to the samples collected at the end of
tuberculosis treatment.
Using changes in blood gene expression to monitor
tuberculosis treatment
There is a great need for new tuberculosis drugs or regi-
mens to shorten treatment and cope with drug resistance.
The lack of easy and economical methods to test tuberculo-
sis drug efficacy is a serious impediment to drug develop-
ment. In later phase III drug efficacy trials, the rate of
tuberculosis relapse over 2 years post-treatment is measured,
and the proof of enhanced or non-inferior drug efficacy
compared to existing drug regimens will require enrolment
of many thousands of patients at vast expense. Currently,
bacteriological approaches, such as the early bactericidal
assay and the sputum conversion rate, are the most com-
monly used methods employed in early clinical studies.
Although they provide some indication of early drug effi-
cacy, particularly against actively replicating bacilli, they are
not sufficient to predict tuberculosis treatment outcome and
do not measure the killing of quiescent or persistent bacte-
rial populations, which could later reactivate.
Host-derived biomarkers that predict tuberculosis treat-
ment outcome could greatly enhance tuberculosis drug devel-
opment (41). Radiological studies using PeT and CT in
cynomolgus macaques can directly demonstrate drug efficacy
at the level of individual granulomas, with different com-
pounds shown to elicit different metabolic effects (42). The
translation of such methodologies to human patients may
allow early efficacy testing of tuberculosis regimens. How-
ever, a simple blood test would be much more easily applied
in large-scale drug efficacy trials and may also be beneficial
for clinical management. We therefore envisage that a test
could be developed based on the blood gene expression
changes that occur during successful tuberculosis treatment
with conventional first-line four drug therapy consisting of
isoniazid, rifampicin, pyrazinamide, and ethambutol. Fur-
thermore, such a test could include genes whose expression
changes both immediately upon treatment initiation, includ-
ing complement and IFN-associated genes, to measure drug
activity potentially against rapidly dividing bacilli, and also
those transcripts that change expression more slowly, such
those encoding B and T-cell genes, potentially reflecting the
restoration of the normal gene expression as slower growing
persistent mycobacterial populations are eradicated or leuko-
cyte populations are restored. This approach would enable
the test to measure the efficacy of compounds or regimens
aimed at a wide range of mycobacterial targets.
A
B
C
Fig. 4. The blood transcriptional signature changes during different phases of treatment. Pathway analysis of the blood transcriptional
signature reveals (A) early changes in complement related genes after 1 week; (B) later changes of other gene sets and restoration of T and B-cell
related genes. (C) There is heterogeneity in the rate of change of gene expression between patients, but large-scale similarity in the overall pattern
of change. (From Cliff et al., Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral
immune response. J Infect Dis 2013; 207(1): pp. 18–29, by permission of Oxford University Press).
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Immunological Reviews 264/2015 95
Cliff et al  Response to TB and treatment
To be useful across human populations, the test would
need to include genes whose expression changes are consis-
tent in different ethnic groups and in patients in different
geographical locations. Furthermore, the test should also
work in HIV+ as well as negative individuals. These issues are
being addressed widely in further blood transcriptomic stud-
ies conducted in different geographical sites. It will also be
important to characterize changes in blood gene expression
that occur during non-standard treatments, such as second-
line drug treatments used in multi-drug resistant tuberculosis.
The development of a test that reflects a successful and
lasting cure would be beneficial for clinical management of
tuberculosis patients. The response to tuberculosis treatment
varies between individuals, which may be reflected by the
blood signature (11, 12), and some risk factors for
increased risk of tuberculosis-relapse after treatment comple-
tion exist. In this regard, people with type 2 diabetes are
not only more likely to develop active tuberculosis upon
infection than non-diabetic people (43) but also are more
likely to suffer tuberculosis-relapse after treatment, treatment
failure, or even death (44). Prediction of successful tubercu-
losis treatment in this population would be particularly valu-
able, and to this end patients are being recruited in different
studies worldwide in patients with both tuberculosis and
type 2 diabetes, which may help to unravel the causal rela-
tionship between the two diseases.
Other methodologies with potential for diagnosis of
tuberculosis
Although gene expression biomarkers from whole blood
RNA have been widely applied to characterize differences
between individuals with active tuberculosis and those with
latent infection or other diseases, other complementary ave-
nues may also be of use to support the analysis of unique
parameters perturbed during tuberculosis disease. While it is
understood that whole blood RNA expression reflects changes
in peripheral blood cells migrating from infected tissue sites,
additional and complementary information can be gained by
measuring molecules that are derived directly from the site of
infection (9, 45, 46). Studies systematically profiling the host
response have employed numerous different methods. Prote-
omic studies have suggested that combinations of plasma or
serum proteins can differentiate individuals with active tuber-
culosis from those latently infected with M. tuberculosis (47),
from other diseases (48), and reflect changes during success-
ful treatment (38, 49). There have been differing reports on
whether cytokines will be of use in treatment monitoring
(reviewed in 1), possibly due to instability of cytokines/
chemokines due to post-transcriptional and post-translational
regulation/degradation (50).
Metabolomic profiling of serum has the potential to dis-
criminate patients with active tuberculosis from latently
infected individuals (51) and has highlighted a potential
pathogenic role for tryptophan metabolism (52), which has
previously been linked with mortality in tuberculosis (53)
and may allow therapeutic limitation of inflammation (46).
Specifically, Weiner et al. (52) analyzed metabolic profiles in
serum samples of tuberculosis patients and healthy controls
and showed that a biosignature based on profiles comprising
less than 20 metabolites can achieve sensitivity and specific-
ity (Fig. 5), although this will need validation in further
cohorts. Some of the predictive metabolites were suggested
to have derived directly from the site of infection. For
example, kynurenine, which was found at significantly
higher levels in the sera of tuberculosis patients than in con-
trols, is synthesized from tryptophan by the enzyme indole-
amine 2,3-dioxygenase 1, induced in macrophages and
dendritic cells in contact with M. tuberculosis, and it is possible
that high kynurenine abundance in serum reflects release of
this molecule from granulomas in the lung. Several pro-
cesses comprising changes in their metabolic components
(including higher levels of kynurenine and cortisol and
lower abundance of lysophosphatidilcholines, which may be
caused by inhibition of phospholipase A2) can be linked to
immunosuppressive mechanisms. In a parallel approach,
cytokines were determined in the same study groups (52).
Distinct cytokines correlated with defined metabolites,
showing the link between metabolite abundance in serum
and the immune processes in response to tuberculosis dis-
ease. For example, the chemokine C-X-C motif chemokine
10 (CXCL10, IP-10), the cytokine interleukin 6, and the
growth factor granulocyte colony-stimulating factor showed
a negative correlation with abundant amino acids, including
glutamine and tryptophan, and positive correlation with
metabolic markers elevated in the sera of tuberculosis
patients, including N–acetylneuraminate and hypoxanthine.
It will be important that these findings are validated in inde-
pendent cohorts (51, 52) and in different locations, as has
been done in the case of blood transcriptomics, to avoid
overestimating diagnostic accuracy, especially with small
sample sizes (54).
A microRNA-223 (miR-223) has been identified as an
upregulated small non-coding RNA in blood and lung
parenchyma of tuberculosis patients and during experimen-
tal mouse models of the disease (55). Deletion of miR-223
rendered mice highly susceptible to acute lung infection and
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it was suggested that miR-223 directly targets the chemo-
attractants CXCL2, CCL3, and IL-6 in myeloid cells. This
study revealed an essential role for a single miRNA in tuber-
culosis and also identified new targets for and assigned bio-
logical functions to miR-223. Although in an early stage,
the potential of miRs for diagnosis and therapy of tubercu-
losis is being considered (56). Likewise, there is discussion
of the potential use of epigenetic markers as diagnostic
markers in adverse immune system conditions and treatment
thereof (57), although again much is to be uncovered as to
the specificity and effectiveness of such approaches. Recent
studies on epigenetic programming in differentiation of
mononuclear phagocytes point to a role of epigenetics in
innate immunity, which has been claimed to play a role in
the non-specific prevention of morbidity and mortality by
the tuberculosis vaccine BCG (58–60).
What did we learn about the immune response from
the transcriptomic analysis of active TB?
Although TNF, IL-12, and the Th1 axis have shown to be
important in both mouse and human for protection against
tuberculosis and other mycobacterial diseases (reviewed in
1), it remains unclear what constitutes a protective immune
response (61) and what factors contribute to the develop-
ment and progress of active tuberculosis disease.
Transcriptomic analyses of blood from patients with tubercu-
losis has revealed a dominant signature of IFN-inducible genes,
including those down-stream of type I and type II (IFN-c) sig-
naling (4, 8, 10, 12), upregulation of complement related
genes (12) and those associated with myeloid function and
inflammation (4, 7, 8, 11, 12, 21, 62) (Fig. 6). In addition, the
signature reflects downregulation of genes encoding B and T-
cell functions (4, 12, 21) (Fig. 6), the latter accounted for by
decreased numbers of T cells in the blood of active tuberculosis
patients (4). This perhaps reflects apoptosis of such cells in the
blood or their migration to the infected tissue (4).
Potential mechanisms whereby type I IFN contributes to
pathogenesis in tuberculosis and other mycobacterial
diseases
The blood transcriptomic approach identified a previously
unappreciated signature of tuberculosis dominated by type I
Fig. 5. Metabolomics uncovers a signature of active tuberculosis in the blood reflecting immunosuppression. Heat map showing fold
changes of small metabolic compounds in the three study groups, tuberculosis patients, healthy uninfected, and latently infected individuals. Fold
changes are relative to the average abundance in the tuberculin skin test (TST) – group. Red indicates relative abundance higher than average in
the TST– group; blue indicates relative abundance lower than average in the TST– group. Horizontal axis: samples belonging to the three study
groups; vertical axis: top 50 compounds selected by variable importance in RF analysis, including compounds that could not be identified, but
were strong predictors of sample status. Color bars above the heat map denote study groups: gray, TST–; green, TST+; red, TBactive. (From
Weiner et al., Plos One 2012) (52).
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IFN, suggesting a potential role of Type I IFN in contributing
to active tuberculosis disease (4, 8, 10, 12). This was sup-
ported by the observations that the signature correlated with
the radiographic extent of disease (4) and was diminished
upon treatment (4, 11, 12). Through microarray analysis of
human tissue from patients with the mycobacterial disease
leprosy (24) and comparison with deposited data on the
blood transcriptional signature of active tuberculosis (8,
23), IFN-inducible transcripts have also been reported in
leprosy. Using these expression data and supported by in
vitro models, this study suggested that in leprosy the balance
of type I and type II IFNs determines a protective or suscep-
tible host immune responses (24). Likewise, in experimental
models of tuberculosis, type I IFN has been shown to have
adverse effects (63–66), although there are conflicting
reports (67). It is of note that adverse effects of Type I
IFN were invariably reported in experimental models of
tuberculosis where mice were infected with clinical isolates
of M. tuberculosis as opposed to the laboratory strain H37Rv
that is largely used. In addition, the experimental mouse
models were on a genetic background other than the
C57Bl/6 or BALB/c that are widely used as experimental
models of tuberculosis (63–65, 68). Elevation of type I IFN
by M. tuberculosis infection of mice in the context of Poly(I)C
(69, 70) or during coinfection with influenza (71) or
through genetic manipulation removing negative regulation
of type I IFN expression by the MAP-kinase TPL-2 (72)
results in exacerbated disease and increased bacterial load,
all via a type I IFN-dependent mechanism.
The mechanisms that mediate IFNa/b-driven disease
exacerbation are not fully understood and will undoubtedly
be complex. Data from investigations of hyper-virulent
A
B
C
a b
c d
Fig. 6. Modular and pathway analysis reveal a dominant IFN-inducible signature in tuberculosis. Modular analysis reveals overabundance of
IFN-inducible genes (M3.1) and myeloid genes (M1.5 and M2.6) and under abundance of B (M1.3) and T cell (M2.8) related genes (A) (4); (B)
(From Cliff et al., Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune
response. J Infect Dis 2013; 207(1): pp. 18–29, by permission of Oxford University Press). (12). (C) The canonical pathway for IFN signaling from
Ingenuity Pathways Analysis; with transcripts over-represented in test set patients with active tuberculosis (1, 4) shaded red. GAS, Gamma-activated
site; ISRE, IFN-sensitive element. Modified from (1, 4). Transcript abundance in whole blood and (c) separated blood leucocyte populations of
representative IFN-inducible genes (from top to bottom: OAS1, IFI6, IFI44, IFI44L, OAS3, IRF7,IFIH1, IFI16, IFIT3, IFIT2, OAS2, IFITM3, IFITM1,
GBP1, GBP5, STAT1, GBP2, TAP1, STAT1, STAT2, IFI35, TAP2, CD274, SOCS1, CXCL10, IFIT5) in active tuberculosis. Transcript abundance/
expression is normalized to the median of the healthy controls. Modified from (A and C modified from Berry et al., Nature 2010) (1, 3, 4).
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strains initially suggested suppression of pro-inflammatory
cytokines and Th1-type immunity (63, 65). Recent data
suggest that type I IFN enhanced migration of inflammatory
monocytes and neutrophils to the lung in M. tuberculosis-
infected mice (68). In keeping with effects on myeloid cells,
recent mechanistic studies have shown that type I IFN can
induce the suppressive cytokine IL-10 (24, 70, 73) and
inhibit the production of the cytokines IL-12 and TNF
important for protection against M. tuberculosis infection (24,
70, 73). Cell-intrinsic type I IFN signals additionally sup-
pressed iNOS production by pulmonary myeloid cells (70).
The induction of immune suppressive IL-10 (reviewed in 1,
74) and IL-1RA by IFNa/b may be part of the mechanism
for this suppression of protective pro-inflammatory cyto-
kines (24, 70, 72, 73). Additionally, type I IFN can block
the ability of IFN-c (type II IFN) to activate macrophages to
control bacterial growth or produce the protective cytokine
IL-12 (24, 73), and hence, the balance of induction of these
two cytokines is critical for the outcome in infection (24,
73). Finally, polarization toward myeloid-derived suppressor
cells, which counteract protective immune responses against
M. tuberculosis, needs to be considered (75). Ablation of mye-
loid-derived suppressor cell effects by all-trans-retinoic acid
in a susceptible mouse model of tuberculosis points to the
potential of host-directed therapy of aberrant myeloid-
derived suppressor cell responses as an adjunct to conven-
tional drug treatment of tuberculosis (75).
IL-1a and IL-1b have been shown recently to inhibit type
I IFN induction in mouse and human macrophages, and
when IL-1 was present in type I IFN-treated cultures, it also
suppressed the pro-bacterial effects downstream of IFNb.
IL-1-induced prostaglandin E2 (PGE2) was also able to
potently inhibit type I IFNs in this context (76). Moreover,
targeting PGE2 during M. tuberculosis infection, either via
direct administration of the prostanoid or enhancement by
5-lipoxygenase blockade with zileuton reversed polyI:
C-mediated type I IFN-driven mortality (76). This has major
implications for the use of zileuton for host-directed therapy
to improve and possibly speed-up the current drug treat-
ment of tuberculosis (76). The use of the blood transcrip-
tome (4, 11, 12) to monitor effective treatment is likely to
be a good supportive approach in clinical trials that utilize
these immunomodulators.
Although high levels of type I IFN may be detrimental to
the outcome of M. tuberculosis infection, it is likely that low
levels at the initiation of an immune response, or in particu-
lar settings, may be protective against this pathogen. For
example, in experiments using Ifngr/Ifnar1/ mice,
IFNa/b is suggested to contribute to host protection in the
absence of the IFNc pathway (77). Furthermore, naturally
Fig. 7. Using a systems biology approach in infectious diseases. This figure defines the strategy for elucidating determinants of protection or
disease in tuberculosis: an iterative process between human disease and experimental models. Modified from O’Garra et al., 2013 (1); O’Garra
et al., 2013 (80); Berry et al., 2013 (3); Blankley et al., 2014 (5).
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occurring mutations in host-protective ISG15 in humans sug-
gests that IFNa/b can induce host-protective responses to
mycobacterial infection, although it is not clear under what
circumstances IFNa/b induces this gene during M. tuberculosis
infection (78). Regardless, many studies demonstrate a
dominant IFN-inducible signature of active tuberculosis (24,
63–65, 70–73, 76), and it is possible that Type I IFN may
contribute to disease progression, since it is higher in
patients with the greatest radiographic lung disease (4) and
is diminished upon effective treatment (4, 11, 12).
Concluding remarks
Evidence to date demonstrates that blood transcriptomics
present a robust approach for studying the immune
response in tuberculosis and other diseases, as similar find-
ings have now been reported from various groups in differ-
ent geographical locations. The findings offer information as
to the immune response underlying the pathogenesis of
tuberculosis and may provide tools toward diagnosis, treat-
ment monitoring, and in the development of host-directed
therapy regimens to support drug treatment. The potential
use of blood transcriptomics in the clinical management of
tuberculosis is likely to support current diagnostic tests and
may help to speed up diagnosis and treatment, thus reduc-
ing transmission. The development of clinic-friendly tools
for supporting the diagnosis of tuberculosis and treatment
monitoring have been suggested to rely on a set of discrimi-
nant classifiers (consisting of between 12 and 100 genes)
that would be easily convertible into a PCR-based affordable
assay, allowing its development in the clinic for tuberculosis
diagnosis. Meta-analyses of diverse studies on the blood
transcriptome of tuberculosis, in the context of other infec-
tious or non-communicable diseases, are required to deter-
mine the unifying signature reflecting tuberculosis versus
other diseases and the blood signature for tuberculosis treat-
ment success. It is possible with advancing technology and
decreasing pricing that a composite whole genome expres-
sion profile, obtained using either microarray or in the
future RNA-Seq, may be useable rather than discriminant
classifiers. This will require the development of sophisticated
tools for rapid integration of complex host transcriptional
signatures, the clinical data and the pathogen identification,
and storage and easy access to such data. Advancement of
bioinformatics tools (37) will also help in uncovering bio-
logical pathways underlying disease susceptibility, including
co-infection, and also help to uncover the comorbidities
caused by infectious and non-communicable diseases. This
will require iterative research approaches between experi-
mental models and human disease (1, 3, 5, 79) (Fig. 7) to
establish the function of immune and inflammatory path-
ways and molecules in resistance or susceptibility to
M. tuberculosis infection.
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